Abstracts tagged "proteoglycans and rheumatoid arthritis (RA)"

Abstract Number: 2549 • 2015 ACR/ARHP Annual Meeting
Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy
Karen M. Doody¹, Stephanie M. Stanford¹, Mattias N. D. Svensson¹, Cristiano Sacchetti¹, Gary S. Firestein², A. Radu Aricescu³ and Nunzio Bottini^1,4, ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, ⁴Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose: RPTPσ (gene PTPRS) is a protein tyrosine phosphatase that binds heparan sulfate- and chondroitin sulfate-containing proteoglycans with its extracellular immunoglobulin domains 1 and…
Abstract Number: 1399 • 2013 ACR/ARHP Annual Meeting
Citrullinated Proteoglycan (Aggrecan) Present In Human Cartilage Is Recognized By Serum Antibodies From Rheumatoid Arthritis Patients
Timea Ocsko¹, Beata Tryniszewska¹, Andras Vida¹, Janos Gal², Gyorgyi Soos², Zoltan Szekanecz³, Tibor A. Rauch¹, Joshua Jacobs¹, Tibor T. Glant¹ and Katalin Mikecz¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Rheumatology, Bacs-Kiskun County Hospital, Kecskemet, Hungary, ³Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary
Background/Purpose: Citrullination is a post-translational protein modification, where arginine (Arg) is converted to citrulline (Cit) by peptidyl arginine deiminases (PADI). The presence of anti-citrullinated protein…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].